Plain-English translation of NCT03675412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand how caffeine affects blood flow in the back of the eye, particularly in people with glaucoma. This study will use a special imaging tool called optical coherence tomography angiography (OCTA) to take detailed pictures of blood vessels in the eye before and after participants take a single 200 mg caffeine tablet. By comparing how eyes respond in people with glaucoma versus healthy people, researchers hope to learn whether caffeine may affect glaucoma progression.
Glaucoma damages the eye's optic nerve, often due to poor blood flow. Caffeine is something many people consume daily, but doctors don't fully understand how it affects blood flow in the eyes of glaucoma patients, so this study aims to fill that knowledge gap.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll come in for a baseline visit where researchers will take special imaging scans of your eye using OCTA technology. You'll then take a single 200 mg caffeine tablet. The study team will repeat the eye scans at 1 hour and 2 hours after you take the caffeine to see if blood flow has changed. The entire process takes a few hours and is non-invasive—no needles or surgery involved.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
Wills Eye
Enrollment target
~80 participants
Started
December 2018
Primary completion
December 2026
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
M. Reza Razeghinejad, MD
Wills Eye Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.